ANTI-CANCER FUSION POLYPEPTIDE

CY1125916T1Undetermined Publication Date: 2026-04-17PIERIS PHARMA GMBH
0 Cites 0 Cited by

Patent Information

Application Number
CY20231100080T
Authority / Receiving Office
CY · CY
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-01-08
Filing Date
2023-02-15
Publication Date
2026-04-17
Estimated Expiration
2043-02-15
Patent Text Reader

Abstract

The disclosure provides a fusion polypeptide specific for CD137 and GPC3, which fusion polypeptide may be useful for directing CD137 clustering and activation of GPC3-positive cancer cells. Such a fusion polypeptide may be useful in many pharmaceutical applications, for example, as an anticancer agent and / or immunomodulator for the treatment or prevention of human diseases, such as a variety of cancers. The disclosure also relates to methods of making the fusion polypeptide described herein, as well as compositions comprising such a fusion polypeptide. The disclosure further relates to nucleic acid molecules encoding such a fusion and nucleic acid molecules. Furthermore, the disclosure includes therapeutic and / or diagnostic uses of such a fusion polypeptide, as well as compositions comprising one or more such fusion polypeptides.
Need to check novelty before this filing date? Find Prior Art